US6133024A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gene expression control
Assignee: Aventis Pharma SA
•
Filing: 1998-05-07
•
Granted: 2000-10-17
•
Expires: 2018-05-07
Abstract
Abstract The present invention relates to new vectors, pharmaceutical compositions containing them, and their therapeutical uses. More particularly, it relates to new molecules capable of acting, in a very selective and efficacious way, on the expression of genes.
Inventors
- 👤 Claude Helene
- 👤 Carine Giovannangeli
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:53
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61P; A61P31/00; A61P31/12; A61P31/20; A61P31/22; A61P35/00; C12N15/1131; C12N15/1132; C12N15/1136; A61K; A61K38/00; C12N2310/00; C12N2310/10; C12N2310/15; C12N2310/152; C12N2310/50; C12N2310/53; C12N2310/531; C12N2310/532; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/788; Y10S977/802; Y10S977/902; Y10S977/904; Y10S977/915; Y10S977/916; Y10S977/92
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
39 words
A recombinant vector, wherein the vector comprises a double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNA in a target cell.
Claim 2
Dependent Claim
39 words
A recombinant vector, wherein the vector comprises a double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNA in a target cell.
Claim 3
Dependent Claim
42 words
The vector according to claim 1, wherein the encoded RNA comprises: (a) a first region which forms a double helix with the single-stranded target nucleic acid, and (b) a second region which forms a triple helix with the double helix thus formed.
Claim 4
Dependent Claim
44 words
The vector according to claim 2, wherein the first region of the RNA forms a double helix by interaction of Watson-Crick type with the targeted single-stranded nucleic acid and then the second region forms a triple helix with this double helix by hydrogen bonds.
Claim 5
Dependent Claim
27 words
The vector according to claim 2, wherein the encoded RNA further comprises an oligonucleotide arm of from 3 to 6 bases between the first and second regions.
Claim 6
Dependent Claim
30 words
The vector according to claim 2, wherein the two regions of the encoded RNA are interrupted, and wherein the encoded RNA further comprises an oligonucleotide arm connecting the two regions.
Claim 7
Dependent Claim
35 words
The vector according to claim 1, wherein the RNA comprises first and second regions which forms a double helix with each other, and thereafter forming a triple helix with the single stranded target nucleic acid.
Claim 8
Dependent Claim
36 words
The vector according to claim 6, wherein the two regions of the RNA form the double helix by pairing of Watson-Crick type, and this double helix interacts with the single-stranded target nucleic acid by hydrogen bonds.
Claim 9
Dependent Claim
128 words
The vector according to claim 1, wherein the RNA comprises: (a) a first region which forms a double helix with an oligopurine region of the single-stranded target nucleic acid, (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid, (c) a first oligonucleotide arm connecting the first and second regions, (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid, (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and (f) a second oligonucleotide arm connecting the third and fourth region.
Claim 10
Dependent Claim
12 words
The vector according to claim 1, wherein the transcription signals are constitutive.
Claim 11
Dependent Claim
12 words
The vector according to claim 1, wherein the transcription signals are regulated.
Claim 12
Dependent Claim
19 words
The vector according to claim 1, wherein the transcription signal is a promoter controlled specifically by RNA polymerase III.
Claim 13
Dependent Claim
36 words
The vector according to claim 1, wherein the double stranded DNA sequence is selected from the group consisting of SEQ ID Nos. 2, 3, 4, 5, 6, 7, 8, 10, 11, 13, 14, 15 and 17.
Claim 14
Dependent Claim
12 words
The vector according to claim 1, which is a replication defective virus.
Claim 15
Dependent Claim
25 words
The vector according to claim 13, wherein the virus is selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus.
Claim 16
Dependent Claim
13 words
The vector according to claim 14, wherein the virus is a defective adenovirus.
Claim 17
Dependent Claim
58 words
A recombinant viral vector selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus, wherein the viral vector comprises more than one double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNAs in a target cell.
Claim 18
Dependent Claim
58 words
A recombinant viral vector selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus, wherein the viral vector comprises more than one double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNAs in a target cell.
Claim 19
Dependent Claim
28 words
The vector according to claim 16, wherein each of the double-stranded DNA sequences encodes a different RNA which forms a triple helix with the single-stranded target nucleic acid.
Claim 20
Dependent Claim
20 words
A composition comprising a vector according to claim 1, wherein said vector is complexed with DEAE-dextran, nuclear proteins, or lipids.
Claim 21
Dependent Claim
18 words
A composition comprising a vector according to claim 1, wherein said vector is incorporated into liposomes or nanoparticles.
Claim 22
Dependent Claim
127 words
An RNA comprising: (a) a first region which forms a double helix with an oligopurine region of a single-stranded target nucleic acid, (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid, (c) a first oligonucleotide arm connecting the first and second regions, (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid, (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and (f) a second oligonucleotide arm connecting the third and fourth region, wherein two triple helices are formed.
Claim 23
Dependent Claim
127 words
An RNA comprising: (a) a first region which forms a double helix with an oligopurine region of a single-stranded target nucleic acid, (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid, (c) a first oligonucleotide arm connecting the first and second regions, (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid, (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and (f) a second oligonucleotide arm connecting the third and fourth region, wherein two triple helices are formed.
References Cited (Backward Citations)
WO1991006626A2
Cited
WO1992019732A1
Cited
WO1993012230A1
Cited
FR2687411A1
Cited
US5624803A
Cited
US5700657A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-10-17 | 2004-04-17 | 2004-10-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-10-17 | 2008-04-17 | 2008-10-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-10-17 | 2012-04-17 | 2012-10-17 | $7700.00 | Window Closed / Lapsed |